IQVIA Biotech Expertise and Resources in JAPAC
Japan continues to attract global sponsors and is currently the number two branded pharmaceutical market, and third largest market overall.
Development and approval times continue to see improvement and in recent years the Japanese government has implemented an accelerated review system that targets investment in innovation and unmet needs offering expediated timelines and extended exclusivity.
Australia & New Zealand
Greater China
India
Korea
Japan
South East Asia
japan
Korea
Greater China
India
south east asia
australia & new zealand
Click to explore more about each region
Japan
Established
1993
Employees
+4,000
Australia and New Zealand (ANZ) have emerged as leading destinations globally for early phase clinical trials with excellent records of quality and timely delivery.
IQVIA Australia and New Zealand (ANZ) has provided fully integrated services for Phase I-IV clinical studies to the pharmaceutical, biotech and device industry. We are the only global CRO in ANZ with full local delivery capabilities, including back end services such as data management, statistics and medical writing. This ensures that sponsors have maximum cost and speed advantages of a full local delivery model whilst benefitting from IQVIA’s experience, quality and worldwide reach.
Established
1993
Employees
+1,200
Australia & New Zealand
IQVIA India has been a pioneer organization in clinical research and has established its presence in India. Over the years, IQVIA India has helped shape the clinical research ecosystem in the country by working closely with key stakeholders such as investigators, institutions and ethics committees. Actively engaging industry and professional associations, regulators, and policy makers, IQVIA India has been at the forefront of driving the advocacy for ethical and responsible research. These efforts have culminated in robust and balanced regulations for clinical research, enabling clinical trial frameworks and steering the course of the industry in India.
Over the years, IQVIA India’s portfolio has grown to a fully accredited laboratory, cardiac safety services, data management, pharmacovigilance, biostatistics and medical writing. Our Team in India has extensive experience in managing studies in Bangladesh and Sri Lanka.
Established
1997
Employees
+17,000
India
IQVIA teams in China, Taiwan and Hong Kong take pride in its contribution to the growth of healthcare industry across Great China. This is the second largest and one of the fastest growing healthcare markets in the world. Headquartered in Shanghai, IQVIA has staffs in over 30 locations across China, including Beijing, Dalian, Guangzhou, Hong Kong, and Taiwan.
As a leading provider of information, innovative technology solutions and contract research services, IQVIA offers a comprehensive portfolio of clinical and commercial solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward.
Employees
+3,300
Greater China
As the leading global CRO, IQVIA Korea offers local and multinational clients a comprehensive portfolio of offerings across clinical development to help biopharmaceutical, medical device and other healthcare organizations succeed in meeting the increasing demand for change and innovation in the South Korean healthcare environment.
IQVIA Korea ranks as the #1 company across biopharmaceutical companies and CROs for IND approvals, according to Korea's Ministry of Food and Drug Safety (MFDS) data.
IQVIA Korea pays close attention to the challenges and opportunities arising from rapid development and change within the complex pharma industry, to provide best-in-class tailored solutions in clinical operation, flexible resourcing and real world insights to meet the needs of our clients. These solutions help our clients develop innovative ideas and foster their global clinical development, resulting in success for their businesses and the advancement of the South Korean healthcare industry.
Established
2000
Employees
+480
Korea
IQVIA has offices in six countries across Southeast Asia (SEA) in Singapore, Malaysia, Thailand, Vietnam, Indonesia and The Philippines. In addition, Pakistan is part of the SEA organization.
Singapore is IQVIA's Asia Pacific headquarter and home to one of its five central labs in the region. A pioneer in the development of the biopharma and life sciences industry within SEA, IQVIA Southeast Asia is committed to providing innovative solutions to meet our biotech customers’ evolving healthcare needs. Our biotech customers come from the Pharmaceutical, MedTech and Consumer Health sectors.
We offer a diverse portfolio of services spanning from the design of clinical development programs to the conduct of clinical trials and all the way to commercialization of products, delivering tailored and high quality solutions for our biotech customers.
Established
1995
Years
+20
Southeast Asia
Years
+20
Studies
+480
Sites
+7,500
Sites
+1,900
Studies
+600
Sites
+760
Studies
+115
Sites
+2,700
Studies
+230
Sites
+2,300
Studies
+400
Sites
+1,200
Studies
+580
Japan continues to attract global sponsors and is currently the number two branded pharmaceutical market, and third largest market overall.
Development and approval times continue to see improvement and in recent years the Japanese government has implemented an accelerated review system that targets investment in innovation and unmet needs offering expediated timelines and extended exclusivity.
japan
Korea
India
south east asia
australia & new zealand
Greater China